The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. METHODS: The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. RESULTS: The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). CONCLUSIONS: A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HRV testing is largely confined to the research setting, the CV reflex tests that assess changes in HRV during standardized clinical challenges such as deep breathing, Valsalva maneuver and supine-to-standing position remain the gold standard tests and are available for clinical care as well.547,614,626”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [626]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to traditional risk factors, hyperglycemia, hyperinsulinemia, and oxidative stress contribute to endothelial damage, leading to poor arterial function and greater susceptibility to atherogenesis ( 45 , 82 , 289 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, studies in people with T2D and early CKD demonstrated the long-term bene fi t of multifactorial intervention on the development of microvascular and macrovascular complications and mortality.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [227]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [216]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.1,2,58–62”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“The benefit of the intensive multifactorial intervention was demonstrated by a significant reduction in the incidence of microvascular complications after 4 years, and a significant 53% risk reduction in macrovascular complications after 8 years.455”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [455]
In the citing paper
“Angiotensin-converting enzyme inhibitors812), angiotensin Ⅱ receptor blockers813), and calcium channel antagonists814) have been reported to be effective for preventing cardiovascular events in patients with DM.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [813]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 2
- 10.1001/jama.241.19.2035 · DOI · Paper page
- 10.1001/archinte.151.6.1141 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,025
Wong, N. D., Zhao, Y., Quek, R. G. W., Blumenthal, R. S., Budoff, M. J., Cushman, M., Garg, P. K., Sandfort, V., Tsai, M. Y., & López, J. A. G. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.015 · Cited by 142
Approaches to prevention of cardiovascular complications and events in diabetes mellitus
Coccheri, S. (2007) · Drugs · doi:10.2165/00003495-200767070-00005 · Cited by 139
Mangiferin: An effective therapeutic agent against several disorders (Review)
Du, S., Liu, H., Lei, T., Xie, X., Wang, H., He, X., Tong, R., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9529 · Cited by 139
“Cardiovascular events may also occur in patients with T2DM, including stroke, myocardial infarction and endothelial dysfunction, which are major physical and economic burdens (37-39).”
Neutrophil–lymphocyte ratio is a reliable predictive marker for early‐stage diabetic nephropathy
Huang, W., Huang, J., Liu, Q., Lin, F.-C., He, Z., Zeng, Z., & He, L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12576 · Cited by 140
Agnelli, G., Cimminiello, C., Meneghetti, G., & Urbinati, S. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02225.x · Cited by 139
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Cohort Profile: The Fremantle Diabetes Study
Davis, T. M. E., Bruce, D. G., & Davis, W. A. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys065 · Cited by 137
Hurst, R. T., & Lee, R. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00010 · Cited by 139
Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update
Tiwari, P. (2015) · Journal of Diabetes Research · doi:10.1155/2015/340838 · Cited by 140
Amato, M. C., Pizzolanti, G., Torregrossa, V., Misiano, G., Milano, S., & Giordano, C. S. D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091969 · Cited by 135
Cardiovascular Disease Prevention and Lifestyle Interventions
Haskell, W. L. (2003) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200309000-00003 · Cited by 136
Clinical Inertia and Outpatient Medical Errors
O’Connor, P. J., Sperl‐Hillen, J. M., Johnson, P. E., Rush, W. A., & Biltz, G. R. (2008) · Journal of Medical Regulation · doi:10.30770/2572-1852-94.2.19 · Cited by 135
Recent advances in the management of diabetic distal symmetrical polyneuropathy
Tesfaye, S. H. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00083.x · Cited by 137
Optimizing the therapeutic benefits of exercise in Type 2 diabetes
Praet, S., & van Loon, L. J. C. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00566.2007 · Cited by 137
Riveline, J., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp181 · Cited by 134
Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'
Chew, G., & Watts, G. F. (2004) · QJM · doi:10.1093/qjmed/hch089 · Cited by 132
Blood pressure control for diabetic retinopathy
Diana, V., Wang, X., Vedula, S. S., Marrone, M. T., Sleilati, G. G., Hawkins, B. S., & Frank, R. N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006127.pub2 · Cited by 138
Daly, C., Fox, K. M., Remme, W. J., Bertrand, M. E., Ferrari, R., & Simoons, M. L. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi225 · Cited by 131
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Picard, M., Tauveron, I., Magdasy, S., Benichou, T., Bagheri, R., Ugbolue, U. C., Navel, V., & Dutheil, F. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251863 · Cited by 130
Sasso, F. C., Pafundi, P. C., Simeon, V., Nicola, L. D., Chiodini, P., Galiero, R., Rinaldi, L., Nevola, R., Salvatore, T., Sardu, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01343-1 · Cited by 130
Comprehensive Cardiovascular Risk Factor Control Improves Survival
Bittner, V., Bertolet, M. H., Barraza, R., Farkouh, M. E., Goldberg, S., Ramanathan, K. B., Redmon, J. B., Sperling, L. S., & Rutter, M. K. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.019 · Cited by 129
Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Krizhanovskii, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2011) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130
Las enfermedades crónicas no transmisibles en México: sinopsis epidemiológica y prevención integral
Córdova-Villalobos, J. Á., Meléndez, J. A. B., Lara‐Esqueda, A., Barquera, S., Rosas-Peralta, M., Hernández‐Ávila, M., de León-May, M. E., Admon, L., & Aguilar-Salinas, C. A. (2008) · Salud Pública de México · doi:10.1590/s0036-36342008000500015 · Cited by 130
Zinman, B., Fulcher, G., Rao, P. V., Thomas, N., Endahl, L. A., Johansen, T., Lindh, R., Lewin, A. J., Rosenstock, J., Pinget, M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62305-7 · Cited by 129
Diagnosis and management of the metabolic syndrome in obesity
Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00221.x · Cited by 131
Dandona, P., Aljada, A., Chaudhuri, A., & Bandyopadhyay, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030178 · Cited by 129
Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
Williams, S. M., Eleftheriadou, A., Alam, U., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00693-0 · Cited by 128
Andreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00559-7 · Cited by 128
Megatrials in type 2 diabetes. From excitement to frustration?
Prato, S. D. (2009) · Diabetologia · doi:10.1007/s00125-009-1352-5 · Cited by 128
Akram, K., Pedersen‐Bjergaard, U., Carstensen, B., Borch‐Johnsen, K., & Thorsteinsson, B. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01880.x · Cited by 128
The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003
Eliasson, B., Cederholm, J., Nilsson, P. M., & Guðbjörnsdóttir, S. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01648.x · Cited by 128
Nuts, metabolic syndrome and diabetes
Kendall, C. W. C., Josse, A. R., Esfahani, A., & Jenkins, D. J. A. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510001546 · Cited by 127
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127
Improving Diabetes Care in Practice
PETERSON, K. A., Radosevich, D. M., O’Connor, P. J., Nyman, J. A., Prineas, R. J., Smith, S. A., Arneson, T. J., Corbett, V., Weinhandl, J. C., Lange, C. J., et al. (2008) · Diabetes Care · doi:10.2337/dc08-2034 · Cited by 127
Idiopathic neuropathy, prediabetes and the metabolic syndrome
Smith, A. G., & Singleton, J. R. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.11.020 · Cited by 129
Libby, P., & Plutzky, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.004 · Cited by 128
Bosch, A., Ott, C., Jung, S., Striepe, K., Karg, M. V., Kannenkeril, D., Dienemann, T., & Schmieder, R. E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0839-8 · Cited by 128
Bakris, G. L. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0713 · Cited by 127
Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario
Mohan, V., Venkatraman, J. V., & Pradeepa, R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400121 · Cited by 127
Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease.
Johnson, M. L., Pietz, K., Battleman, D. S., & Beyth, R. J. (2004) · PubMed · Cited by 125
Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P. (2024) · Diabetes Care · doi:10.2337/dc23-1520 · Cited by 124
Analysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications
Gupta, S., Maratha, A., Siednienko, J., Natarajan, A., Gajanayake, T., Hoashi, S., & Miggin, S. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-07230-8 · Cited by 127
Oba, K. (2011) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.48.640 · Cited by 124
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 124
Chapman, M. J., & Sposito, A. C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.004 · Cited by 123
Evidence-based Practice Guideline for the Treatment of CKD
(2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0237-8 · Cited by 124
Dirks, J. H., de Zeeuw, D., Agarwal, S. K., Atkins, R. C., Correa‐Rotter, R., D’Amico, G., Bennett, P. H., Nahas, M. E., Valdés, R. H., Kaseje, D. A. N., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09800.x · Cited by 122
Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management
El-Atat, F., McFarlane, S. I., & Sowers, J. R. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0072-y · Cited by 121
Brath, H., Morak, J., Kästenbauer, T., Modre‐Osprian, R., Strohner‐Kästenbauer, H., Schwarz, M., Kort, W., & Schreier, G. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12184 · Cited by 121
Ravaut, M., Sadeghi, H., Leung, K. K., Volkovs, M., Kornas, K., Harish, V., Watson, T., Lewis, G. F., Weisman, A., Poutanen, T., et al. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00394-8 · Cited by 121
Lindhardt, M. K., Persson, F., Currie, G. E., Pontillo, C., Beige, J., Delles, C., von der Leyen, H. E., Mischak, H., Navis, G. J., Noutsou, M., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010310 · Cited by 122
Friis, K., Vind, B. D., Simmons, R. K., & Maindal, H. T. (2016) · Journal of Diabetes Research · doi:10.1155/2016/7823130 · Cited by 121
Idiopathic neuropathy patients are at high risk for metabolic syndrome
Smith, A. G., Rose, K., & Singleton, J. R. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.005 · Cited by 122
Stroke in patients with diabetes mellitus
Mankovsky, B., & Ziegler, D. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.490 · Cited by 123
New Drugs for Type 2 Diabetes Mellitus
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 122
Impact of subjective sleep quality on glycemic control in type 2 diabetes mellitus
Tsai, Y.-W., Kann, N.-H., Tung, T.-H., Chao, Y.-J., Lin, C., Chang, K.-P., Chang, S.-S., & Chen, J.-Y. (2011) · Family Practice · doi:10.1093/fampra/cmr041 · Cited by 125
Dietz, R., & Rauch, B. (2003) · Zeitschrift für Kardiologie · doi:10.1007/s00392-003-0960-1 · Cited by 124
Abdominal obesity: The cholesterol of the 21st century?
Després, J., Arsenault, B. J., Côté, M., Cartier, A., & Lemieux, I. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)71043-2 · Cited by 122
Diabetic peripheral neuropathy may not be as its name suggests
Tesfaye, S. H., Selvarajah, D., Gandhi, R. A., Greig, M., SHILLO, P. R., Fang, F., & Wilkinson, I. D. (2015) · Pain · doi:10.1097/j.pain.0000000000000465 · Cited by 122
Glycemic Control and Cardiovascular Events in Diabetic Hemodialysis Patients
Drechsler, C., Krane, V., Ritz, E., März, W., & Wanner, C. (2009) · Circulation · doi:10.1161/circulationaha.109.857268 · Cited by 121
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Pareek, A., Chandurkar, N., & Naidu, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611290 · Cited by 119
Astrup, A. S., Tarnow, L., Pietraszek, L., Schalkwijk, C. G., Stehouwer, C. D. A., Parving, H., & Rossing, P. R. (2008) · Diabetes Care · doi:10.2337/dc07-1960 · Cited by 119
Self-citationMix, T.-C. H., Brenner, R. M., Cooper, M. E., de Zeeuw, D., Ivanovich, P. T., Levey, A. S., McGill, J. B., McMurray, J. J. V., Parfrey, P. S., Parving, H., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.047 · Cited by 119
Self-citationOgura, Y., Kitada, M., Xu, J., Monno, I., & Koya, D. (2020) · Aging · doi:10.18632/aging.103410 · Cited by 118
Fornos, J. A., de Andrés, N. F., Andrés, J. C., Guerra, M., & Egea, B. (2006) · Pharmacy World & Science · doi:10.1007/s11096-006-9003-0 · Cited by 124
Ebrahimi, M. T., Sharifi, N., Farrokhian, A., Raygan, F., Karamali, F., Razzaghi, R., Taheri, S., & Asemi, Z. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-105441 · Cited by 121
Lipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 118
Screening for Diabetes and Prediabetes
Duan, D., Kengne, A. P., & Echouffo-Tcheugui, J. B. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.002 · Cited by 131
Wright, A. K., Suárez‐Ortegón, M. F., Read, S. H., Kontopantelis, E., Buchan, I. E., Emsley, R., Sattar, N. A., Ashcroft, D. M., Wild, S. H., & Rutter, M. K. (2020) · Circulation · doi:10.1161/circulationaha.120.046783 · Cited by 118
Glucose Metabolism in Patients with Essential Hypertension
Puig, J. G., Ruilope, L. M., Luque, M., Fernández, J., Ortega, R., & Dal−Ré, R. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.010 · Cited by 117
Nicholls, S. J., Tuzcu, E. M., Wolski, K., Bayturan, Ö., Lavoie, A., Uno, K., Kupfer, S., Pérez, A., Nesto, R. W., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.055 · Cited by 114
Nurse Practitioner Care Improves Renal Outcome in Patients with CKD
Peeters, M. J., van Zuilen, A. D., van den Brand, J. A. J. G., Bots, M. L., van Buren, M., ten Dam, M. A. G. J., Kaasjager, K. A. H., Ligtenberg, G., Sijpkens, Y. W. J., Sluiter, H. E., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121222 · Cited by 120
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Effects of Dapagliflozin on Cardiovascular Risk Factors
Ptaszynska, A., Hardy, E., JOHNSSON, E. K., Parikh, S. J., & List, J. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2667 · Cited by 115
Stanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 123
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 113
Diabetes and Hypertension: Pathogenesis, Prevention and Treatment
Landsberg, L., & Molitch, M. E. (2004) · Clinical and Experimental Hypertension · doi:10.1081/ceh-200031945 · Cited by 112
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koška, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 115
Update in Renal Transplantation
Magee, C., & Pascual, M. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1373 · Cited by 112
Glycemic Control and Burnt‐Out Diabetes in ESRD
Kovesdy, C. P., Park, J. C., & Kalantar‐Zadeh, K. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00701.x · Cited by 113
Oral antidiabetic agents in type 2 diabetes
Levetan, C. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x178766 · Cited by 112
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Bahiru, E. M., de Cates, A. N., Farr, M. R. B., Jarvis, M. C., Palla, M., Rees, K., Ebrahim, S. B. J., & Huffman, M. D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009868.pub3 · Cited by 112
Overcome Clinical Inertia to Control Systolic Blood Pressure
O’Connor, P. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2677 · Cited by 110
Ali, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Shivashankar, R., Ajay, V. S., Unnikrishnan, A. G., Menon, V. U., Varthakavi, P. K., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2807 · Cited by 114
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 109
Singh, P. P., Mahadi, F., Roy, A., & Sharma, P. (2009) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-009-0062-6 · Cited by 110
Residual microvascular risk in diabetes: unmet needs and future directions
Fioretto, P., Dodson, P. M., Ziegler, D., & Rosenson, R. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.213 · Cited by 110
Monitoring Kidney Function in Type 2 Diabetic Patients With Incipient and Overt Diabetic Nephropathy
Rossing, P. R., Rossing, K., Gæde, P., Pedersen, O., & Parving, H.-H. (2006) · Diabetes Care · doi:10.2337/diacare.2951024 · Cited by 109
Self-citationWannamethee, S. G., Shaper, A. G., & LENNON, L. T. (2004) · Heart · doi:10.1136/hrt.2003.026104 · Cited by 109
Experience-based group education in Type 2 diabetes
Sarkadi, A., & Rosenqvist, U. (2004) · Patient Education and Counseling · doi:10.1016/j.pec.2003.10.009 · Cited by 109
Health promotion in hospitals: Evidence and quality Management
Groene, O., & García-Barbero, M. (2005) · Cited by 109
Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.
Mayfield, J. A., & White, R. D. (2004) · PubMed · Cited by 108
Predictive Value of Silent Myocardial Ischemia for Cardiac Events in Diabetic Patients
Valensi, P. E., Pariès, J., Brulport-Cerisier, V., Torremocha, F., Sachs, R.-N., Vanzetto, G., Cosson, E., Lormeau, B., Attali, J. R., Maréchaud, R., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2722 · Cited by 108
Weil, E. J., Fufaa, G., Jones, L. I., Lovato, T., Lemley, K. V., Hanson, R. L., Knowler, W. C., Bennett, P. H., Yee, B., Myers, B. D., et al. (2013) · Diabetes · doi:10.2337/db12-1512 · Cited by 108
Charles, M., Ejskjær, N., Witte, D. R., Borch‐Johnsen, K., Lauritzen, T., & Sandbæk, A. (2011) · Diabetes Care · doi:10.2337/dc11-0903 · Cited by 108
Intensive Integrated Therapy of Type 2 Diabetes
Gæde, P., & Pedersen, O. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s39 · Cited by 108
Self-citationBushnell, C., Culebras, A., DeGraba, T. J., Goldstein, B. A., Adams, R. J., Alberts, M. J., & Appel, L. J. (2006) · Cited by 108
Fixed-dose combination therapy for the prevention of cardiovascular disease
de Cates, A. N., Farr, M. R. B., Wright, N., Jarvis, M. C., Rees, K., Ebrahim, S. B. J., & Huffman, M. D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009868.pub2 · Cited by 109
Metadata
- Authors
- Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Herlev Hospital (DK)
- Roskilde Sygehus (DK)
- Aarhus University (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-30
- Volume
- 348
- Issue
- 5
- Pages
- 383-393
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139634859
- Cited by
- 4,378
- References
- 26
- Citations by year
- 2026: 47 · 2025: 71 · 2024: 108 · 2023: 110 · 2022: 102 · 2021: 137 · 2020: 142 · 2019: 133 · 2018: 171 · 2017: 143 · 2016: 158 · 2015: 169 · 2014: 198 · 2013: 184 · 2012: 235
- FWCI
- 178.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, multifactorial intervention, microalbuminuria, tight glycemic control, hyperglycemia, hypertension, dyslipidemia, aspirin, myocardial infarction, stroke, kidney disease, retinopathy, autonomic neuropathy
- MeSH terms
- Amputation, Surgical, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Obesity, Risk Factors, Vitamins, Exercise, Smoking Cessation, Diet, Fat-Restricted, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
